ANNOUNCEMENT
Conference on Guidelines for Laboratories Performing
HIV-related CD4 T-Cell Determinations
November 14-15, 2001
Disney Coronado Springs Hotel
Orlando, FL
SPONSOR: Centers for Disease Control and Prevention
JOINT Association of Public Health Laboratories
SPONSORS: Clinical Cytometry Society
PURPOSE: Obtain input from the clinical cytometry community with
regard to possible revision of the "1997 Revised Guidelines
for Performing CD4+ T-Cell Determinations in Persons
Infected
with Human Immunodeficiency Virus (HIV)"
MMWR 46:RR-2, January 10, 1997.
TARGET Laboratorians, health scientists, physicians, and other
AUDIENCE: members of the health care team who have responsibility
for or an interest in assuring the quality of CD4 T-cell
testing services.
ISSUES: * Need to revise the current CD4 T-cell testing guidelines
* Inter- and intralaboratory variability in CD4 and CD8
T-cell determinations
* Absolute vs. percentage T-cell subset values, which
is better as a clinical tool and why?
* Gating strategies: use of light scatter and CD45
* Absolute CD4 and CD8 cell counts using flow cytometry:
inter- and intralaboratory variability
* 3- and 4-color panels for CD4 T-cell determinations:
antibody combinations, number of tubes needed for a
panel, QA and QC issues
* Approaches to validation of new methods
* Quality control and quality assurance
ABSTRACTS: The areas of interest and instructions for submitting
abstracts for oral presentations are located at:
http://www.phppo.cdc.gov/mlp/cd4.asp
COMMENTS: Comments/suggestions related to the meeting and issues
to be discussed may be submitted at:
http://www.phppo.cdc.gov/mlp/cd4_mailform.asp
COST: There is no registration cost for participants. No
accommodations or meals are provided.
REGISTRATION: Meeting registration may be completed online at:
http://www.phppo.cdc.gov/mlp/cd4_registration.asp or,
alternatively, hard copies of the program and
registration form may be obtained by contacting:
G. David Cross, M.S.
Centers for Disease Control and Prevention
4770 Buford Highway, N.E., Mailstop G-23
Atlanta, GA 30341-3717
(770) 488-8091
gcross@cdc.gov
This meeting will be held in the same conference hotel and will
begin the day following the 16th Annual Clinical Applications
of Cytometry (CAC) meeting.
+++++++++++++++++++++MEETING SCHEDULE++++++++++++++++++++++++++
The CD4 T-cell Guidelines Consensus Meeting
November 14-15, Orlando, Florida
TENTATIVE SCHEDULE
8:30-9:00
Introduction: Jan Nicholson
Where we have been, where we are now, where we are going
in CD4 cell testing. History of CDC guideline development
and their impact. The process for revision for year 2002.
Moderator: Frank Mandy
9:00-9:30
Quality Assurance Programs (MPEP): Barbara Slade
What do we know about how well laboratories in the US are
performing CD4 and CD8 cell testing?
9:30-10:00
Gating Strategies for T-cell Subsets have Evolved: Frank Mandy
Concepts of gating and selection criteria have changed:
Pros and cons of homogeneous vs. heterogeneous gating.
10:00-10:30 BREAK
Moderator: Carol Schnizlein-Bick
10:30-11:00
One platform for absolute counting (Part One) Mo O'Gorman
Absolute cell counting using Flow Count beads; 2- vs. 3- vs.
4-color immunophenotyping: intra and interlaboratory variability.
11:00-11:30
One platform for absolute counting (Part Two) Carol Schnizlein-Bick
Absolute cell counting TruCount beads; 3- vs. 4-color
immunophenotyping: intra and interlaboratory variability.
11:30-12:00
Quality Assurance Programs for CD4 T-cells for ACTG Becky Gelman
What have we learned from the ACTG QAP about CD4 T-cell testing?
What value does CD45 gating bring to laboratory results?
12:00-12:30 QUESTION AND ANSWERS SESSION FOR ALL MORNING SPEAKERS
12:30-2:00 LUNCH
2:00-3:45 PARALLEL WORKSHOPS
Workshop Group A
Absolute cell counting using FlowCount fluorospheres Beckman Coulter
Workshop Group B
Absolute cell counting using TruCount fluorospheres Becton Dickinson
Moderator:
Chris Tsoukas
3:45-4:15
T-cell subset analysis from a clinician's perspective Chris Tsoukas
The CD4 T-cell legend is not the full story.
4:15-5:00 ORAL PRESENTATIONS (ten minutes each)
Selected from submitted abstracts (4 or 5)
Day Two
Moderator: Mo
O'Gorman
8:00-8:30
Issues of compensation, how to succeed with
3 or 4 colors? Mario
Roederer
Software versus hardware compensation in the 21st century
8:30-9:00
Has the single tube assay arrived? Mo O'Gorman
Can one get the same results from 1 tube as from multiple tubes?
Considerations for increasing the number of antibodies per tube:
technical requirements for antibody combinations; quality control
issues. Are isotype controls needed for CD4 and CD8 T-cell
determinations?
9:00-9:30
Percentage and absolute T-cell subsets are no longer
two solitudes Michael Lederman
During clinical evaluation of HIV infection the benefits of using
CD4 and CD8 percentages and absolute number values.
9:30-10:00 BREAK
Moderator:
Howard Shapiro
10:00-10:30
Quality control systems for immunophenotyping Katharine Muirhead
Methods available for quality control and quality assurance.
How are these applied in single-platform technologies and
multicolor panels?
10:30-11:00
Quality Assessment issues in the Global Village Michele Bergeron
We have the tools, are we implementing them where
they are needed the most?
11:00-11:30
Clinical cytometers moved from the floor to the
desktop where next? Howard Shapiro
Emerging new technologies that will improve or replace current
clinical diagnostic tools to fight HIV disease.
11:30-12:00 QUESTIONS AND ANSWER SESSION FOR ALL MORNING SPEAKERS
12:00-12:15
Closing remarks Jan
Nicholson
++++++++++++++++++++++++++++CALL FOR ABSTRACTS+++++++++++++++++++++++++++++
The National Conference on Guidelines for Laboratories Performing
HIV-related CD4 T-cell Determinations, held in Orlando, FL,
November 14 and 15, 2001 is seeking data for oral presentations.
We will select a limited number of abstracts for oral presentation,
based in the scope of the study, the completeness of the data, and
how well it addresses one of the questions posed below.
1. What is the minimum number of tubes required for accurate
and reliable CD4 and CD8 cell determinations?
2. Which provides the most accurate and reproducible results:
CD45 gating or light scatter gating?
3. Is the inclusion of isotype controls in a monoclonal
antibody
panel for CD4 and CD8 determinations necessary?
4. Which provides the most accurate and reproducible results:
4-color, 3-color, or 2-color panels?
5. Which provides the most accurate and reproducible results
for CD4 and CD8 cell counts: single-platform methods or
multi-platform methods?
The abstract may not exceed 250 words, should be submitted in English,
and must be received no later than Oct. 15, 2001. It is preferred that
the abstract be submitted as a word processing file attached to an
e-mail (phpdls@cdc.gov). Otherwise, the abstract should be submitted as
text in the body of an e-mail or conventionally delivered hard copy.
Abstracts will be included in the program book. Notification of
acceptance for oral presentation will be sent by Nov. 1, 2001.
Instructions about abstract submission are also available on our website
(http://www.phppo.cdc.gov/mlp/cd4.asp).
Please address all non-electronic inquiries or abstract submissions to:
David Cross
Division of Laboratory Systems
Public Health Practice Program Office
Centers for Disease Control and Prevention
Mailing address: Overnight/Priority
delivery address
4770 Buford Hwy. N.E., (FedEx, United Parcel
Service etc.)
Mailstop G-23 CDC/Williams Building
Atlanta GA, USA 30341-3717 2877 Brandywine Road, Room
#2009
Atlanta, GA 30341
Mr. Cross may also be contacted at:
Phone: (01) 770-488-8091
FAX: (01) 770-488-8275
This archive was generated by hypermail 2b29 : Sun Jan 05 2003 - 19:01:32 EST